# Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

> **NCT05911295** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 412 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** disitamab vedotin
- **DRUG:** pembrolizumab
- **DRUG:** gemcitabine
- **DRUG:** cisplatin
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT05911295
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-22
- **Primary completion:** 2026-06-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- RemeGen Co., Ltd.
- Merck Sharp & Dohme LLC

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911295, "Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05911295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*